PharmaLundensis new Business Plan

PharmaLundensis Business Plan Spring 2026.
PharmaLundensis is now looking for contacts with international investors to secure MUSD 6 to finance GMP production of Phal-501 and Proof-of-concept clinical studies on patients with COPD and chronic fatigue syndorme. An updated Business plan is presented which will be used in these contacts.